

FORM PTO - 1449 (Substitute)				ATTY. DOCKET NO.		SERIAL NO.	
LIST OF PRIOR ART CITED BY APPLICANT <i>(Use several sheets if necessary)</i>				APPLICANT			
				FOSTER, HD.			
				FILING DATE		GROUP	
				06/23/03			
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	AA	5102908	1992	ALBECK	514	467	JUNE 1, 1990
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
FOREIGN PATENT DOCUMENTS							
	AL						
	AM						
	AN						
	AO						
	AP						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AR	TAYLOR, BHAT	1997	HIV-1 ENCODES A	393-4		
		ET AL		SEQUENCE...			
	AS	ZHAO, COX	2000	MOLECULAR	6356-61		
		ET AL		MODELING			
	AT	MAIORINO,	1998	PROBING THE	118-121		
		AUMANN ET AL		CATALYTIC			
		TRIAD					
EXAMINER /Frank Choi/				DATE CONSIDERED 10/06/2009			
<i>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</i>							

4. Amar M.B., Morisset R., Ghadirian P., Fathie K. GSPH-1: A potent stimulant of CD8+ Lymphocytes in HIV-infected patients. J Neural Orthop Med Surg 1997; 17:196-200.
5. Hori K., Hatfield D., Maldarelli F., Lee B.J., Clouse K.A. Selenium Supplementation suppresses tumor necrosis factor alpha-induced human immunodeficiency virus type 1 replication in vitro. *AIDS Res Retroviruses* 1997; 13(15), 1325-1332.
6. Shor-Posner G., Miguez M.J., Pineda L.M., Rodriguez A., Ruiz P., Castillo G., Burbano X., Lecusay R., Baum M. Impact of selenium status on the pathogenesis of mycobacterial disease in HIV-1-infected drug users during the era of highly active antiretroviral therapy. *J Acquir Immune Defic Syndr* 2002; 29(2): 169-173.
7. Campa A., Shor-Posner G., Indacochea F., Zhang G., Lai H., Asthana D., Scott G.B., Baum M.K. Mortality risk in selenium-deficient HIV-positive children. *J Acquir Immun Defic Syndr Hum Retrovirol* 1999; 20(5): 508-513.
8. Cowgill V.M. The distribution of selenium and mortality owing to Acquired Immune Deficiency Syndrome in the Continental United States. Biological Trace Element Research 1997; 56: 43-61.
9. James J.S. NAC: First controlled trial, positive results. *AIDS Treatment News* 07/05/96. <http://www.aids.org/atn/a-266-01.html>
10. Martin J.A., Sastre J., de la Asunción J.G., Pallardó F.V., Viña J. Hepatic gamma-cystathionase deficiency in patients with AIDS. *JAMA* 2001; 285(11): 1444-1445.
11. Passwater R.A. N-Acetylcysteine (NAC): An old nutrient attracts new research. HealthWorld Online Interviews.
12. Fowkes S.W. Tryptophan metabolism in chrome disease and AIDS. The Megahealth Society Online.

13. Droge W., Holm E. Role of cysteine and glutathione in HIV infection and other diseases associated with muscle wasting and immunological dysfunction. *FASEB J* 1997; 11(13):1077-1089.
14. Kinscherf R., Fischback T., Mihm S., Roths S., Hohenhaus-Sievert E., Weiss C., Edler L., Bartsch P., Droge W. Effects of glutathione depletion and oral N-acetyl-cysteine treatment on CD4 and CD8+ cells. *FASEB J* 1994; 8(6): 448-451.
15. Noyer C.M., Simon D., Borczuk A., Brandt L.J., Lee M.J., Nehra V. A double-blind placebo-controlled pilot study of glutamine therapy for abnormal intestinal permeability in patients with AIDS. *Am J Gastroenterol* 1998; 93(6): 972-975.
16. Gil L., Martinez G., Gonzalez I., Tarinas A., Alvarez A., Giuliani A., Molina R., Tapanes R., Perez J., Leon O.S. Contribution to characterization of oxidative stress in HIV/AIDS patients. *Pharmacol Res* 2003; 47(3): 217-224.

BY THE APPLICANT

17. Foster H.D. AIDS and the "Selenium CD4T cell tailspin" The geography of a pandemic. *Townsend Letters for Doctors and Patients* 2000; 209: 94-99.
18. Foster H.D. How HIV-1 kills: implications for the treatment and prevention of AIDS. *Townsend Letter for Doctors and Patients* 2002; 255: 76-78.
19. Foster H.D. *What really causes AIDS* 2002; Victoria: Trafford Publishing.
20. Foster H.D. Why HIV-1 has diffused so much more rapidly in Sub-Saharan Africa than in North America. *Medical Hypotheses* 2003; 60(4): 611-614.
21. Foster H.D. How HIV-1 causes AIDS: Implications for prevention and treatment. Under review by Medical Hypotheses.

22. Foster H.D. Halting the AIDS pandemic. Chapter in EarthWorks: Geographical Solutions to 100 Problems. Association of American Geographers Centennial Volume, 2004 expected, Kluwer. (8 pages typed)
23. Foster H D. AIDS: the only logical solution. Accepted October 4, 2003 by Nexus. Will appear in November – December 2003 and January – February 2004 volumes of this magazine.
24. Foster H.D, Hu W., Hong Q. Micronutrients in pathogenesis and treatment of AIDS. Foreign Medical Sciences Section of Medgeography 2003; 6, 24, 2: 49-53 (in Chinese).
25. Foster H.D. Halting the AIDS pandemic now. British Medical Journal Online. (bmj.com) <http://bmjjournals.com/cgi/eletters/325/7375/1257>
26. Foster H D. Aids in South Africa: The Third Dimension. British Medical Journal Online (bmj.com) <http://bmjjournals.com/cgi/eletters/326/7387/495#30119>
27. Foster H D. AIDS prevention: the missing key component. British Medical Journal Online (bmj.com). <http://bmjjournals.com/cgi/eletters/326/7403/1389>

09/30/2009

/Frank Choi/